Targeting the central nervous system: In vivo experiments with peptide-derivatized nanoparticles loaded with Loperamide and Rhodamine-123

Journal of Controlled Release

Volumn 122, Issue 1, 2007, Pages 1-9

  Tosi, G ^a   Costantino, L ^a   Rivasi, F ^a   Ruozi, B ^a   Leo, E ^a   Vergoni, A V ^a   Tacchi, R ^a   Bertolini, A ^a   Vandelli, M A ^a   Forni, F ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

Brain; Nanoparticles; Opioid; PLGA; Targeting

Indexed keywords

BIOCOMPATIBILITY; BLOOD; BRAIN; DRUG PRODUCTS; DYES; NANOPARTICLES; PEPTIDES; POLYESTERS;

BLOOD BRAIN BARRIERS (BBB); OPIOIDS; PEPTIDIC MOIETIES;

NEUROLOGY;

LOPERAMIDE; NANOPARTICLE; RHODAMINE 123;

ANIMAL EXPERIMENT; ARTICLE; BLOOD BRAIN BARRIER; BRAIN REGION; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG TARGETING; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; ANTIDIARRHEALS; BLOOD-BRAIN BARRIER; BRAIN; DRUG DELIVERY SYSTEMS; LACTIC ACID; LOPERAMIDE; MALE; NANOPARTICLES; OLIGOPEPTIDES; PAIN MEASUREMENT; POLYGLYCOLIC ACID; POLYMERS; RATS; RATS, WISTAR; RHODAMINE 123;

EID: 34548041658     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2007.05.022     Document Type: Article

References (48)

1. Ricci M., Blasi P., Giovagnoli S., and Rossi C. Delivering drugs to the central nervous system: a medicinal chemistry or a pharmaceutical technology issue?. Curr. Med. Chem., 13 (2006) 1757-1775
2. Hawkins B.T., and Davis T.P. The blood-brain barrier/neurovascular unit in health and disease. Pharm. Rev., 57 (2005) 173-185
3. Edwards R.T. Drug delivery via the blood-brain barrier. Nat. Neurosci. 4 (2001) 221-222
4. Reddy J.S., and Venkateswarlu V. Novel delivery systems for drug targeting to the brain. Drugs Future, 29 (2002) 63-83
5. Hau P., Favel K., Baumgart U., Rummele P., Grauer O., Bock A., Dietmaier C., Dietmaier W., Dietrich J., Dudel C., Hubner F., Jauch T., Drechsel E., Kleiter I., Wismeth C., Zellner A., Brawanski A., Steinbrecher A., Marienhagen J., and Bogdahn U. Pegylated liposomal doxorubicin-efficacy in patients with recurrent high-grade glioma. Cancer, 100 (2004) 1199-1207
6. Kreuter J. Nanoparticulate system for brain delivery of drugs. Adv. Drug Deliv. Rev. 47 (2001) 65-81
7. Huwyler J., Wu D., and Pardridge W.M. Brain drug delivery of small molecules using immunoliposomes. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 14164-14169
8. Pardrige W.M. Blood-brain barrier drug targeting: the future of brain drug development. Mol. Interv. 3 (2003) 90-105
9. Lockman R., Mumper R.J., Khan M.A., and Allen D.D. Nanoparticle technology for drug delivery across the blood-brain barrier. Drug Dev. Ind. Pharm. 28 (2002) 1-13
10. Garcia-Garcia E., Andrieux K., Gil S., and Couvreur P. Colloidal carriers and blood-brain barrier (BBB) translocation: a way to deliver drugs to the brain?. Int. J. Pharm. 298 (2005) 274-2929
11. Tröester S.D., and Kreuter J. Influence of the surface properties of low contact angle surfactants on the body distribution of 14C-poly(methyl methacrylate) nanoparticles. J. Microencapsul. 9 (1992) 19-28
12. Calvo J.P., Gouritin B., Chacun H., Desmaele D., D'Angelo J., Noel J.P., Georgin D., Fattal E., Andreux J.P., and Couvreur P. Long-circulating PEGylated polycyanoacrylate nanoparticles as new drug carrier for brain delivery. Pharm. Res. 18 (2001) 1157-1166
13. Kreuter J., Petrov V.E., Kharkevich D.A., and Alyautdin R.N. Influence of the type of surfactant on the analgesic effects induced by the peptide dalargin after its delivery across the blood-brain barrier using surfactant-coated nanoparticles. J. Control. Release 49 (1997) 81-87
14. Alyautdin R.N., Petrov V.E., Langer K., Berthold A., Kharkevich D.A., and Kreuter J. Delivery of loperamide across the blood-brain barrier with polysorbate 80-coated polybutylcyanoacrylate nanoparticles. Pharm. Res. 14 (1997) 325-328
15. Ambruosi A., Khalansky A.S., Yamamoto H., Gelperina S.E., Begley D.J., and Kreuter J. Biodistribution of polysorbate 80-coated doxorubicin-loaded [14C]-poly(butyl cyanoacrylate) nanoparticles after intravenous administration to glioblastoma-bearing rats. J. Drug Target. 14 (2006) 97-105
16. 14C]poly(butyl cyanoacrylate) nanoparticles after i.v. administration in rats. J. Drug Target. 13 (2005) 535-542
17. Steiniger S.C.J., Kreuter J., Khalansky A.S., Skidan I.N., Bobruskin A.I., Smirnova Z.S., Severin S.E., Uhl R., Kock M., Geiger K.D., and Gelperina S.E. Chemotherapy of glioblastoma in rats using doxorubicin-loaded nanoparticles. Int. J. Cancer 109 (2004) 759-767
18. Gulyaev A.E., Gelperina S.E., Skidan I.N., Antropov A.S., Kivman G.Y., and Kreuter J. Significant transport of doxorubicin into the brain with polysorbate 80-coated nanoparticles. Pharm. Res, 16 (1999) 1564-1569
19. Friese A., Seiller E., Quack G., Lorenz B., and Kreuter J. Increase of the duration of the anticonvulsive activity of a novel NMDA receptor antagonist using poly(butylcyanoacrylate) nanoparticles as a parenteral controlled release system. Eur. J. Pharm. Biopharm. 49 (2000) 103-109
20. Olivier J.C., Fenart L., Chauvet R., Pariat C., Cecchelli R., and Couet W. Nanoparticle technology for drug delivery across the blood-brain. Pharm. Res. 16 (1999) 1836-1842
21. Michaelis K., Hoffmann M.M., Dreis S., Herbert E., Alyautdin R.N., Michaelis M., Kreuter J., and Langer K. Covalent linkage of apolipoprotein E to albumin nanoparticles strongly enhances drug transport into the brain. J. Pharm. Exp. Ther. 317 (2006) 1246-1253
22. Kreuter J., Hekmatara T., Dreis S., Vogel T., Gelperina S., and Langer K. Covalent attachment of apolipoprotein A-I and apolipoprotein B-100 to albumin nanoparticles enables drug transport into the brain. J. Control. Release 118 (2007) 54-58
23. Costantino L., Gandolfi F., Tosi G., Rivasi F., Vandelli M.A., and Forni F. Peptide-derivatized biodegradable nanoparticles able to cross the blood-brain barrier. J. Control. Release 108 (2005) 84-96
24. Costantino L., Gandolfi F., Bossy-Nobs L., Tosi G., Gurny R., Rivasi F., Vandelli M.A., and Forni F. Nanoparticulate drug carriers based on hybrid poly(d,l-lactide-co-glycolide)-dendron structures. Biomaterials 27 (2006) 4635-4645
25. Dechy-Cabaret O., Martin-Vaca B., and Bourissou D. Controlled ring-opening polymerization of lactide and glycolide. Chem. Rev. 104 (2004) 6147-6176
26. Emerich D.F., Snodgrass P., Pink M., Bloom F., and Bartus R.T. Central analgesic actions of loperamide following transient permeation of the blood brain barrier with Cereport (RMP-7). Brain Res. 801 (1998) 259-266
27. de Lange E.C., de Bock G., Shinkel A.H., de Boer A.G., and Breimer D.D. BBB transport using MDR 1A (-/-) and wild-type mice. Total brain versus microdialysis concentration profiles of Rhodamine-123. Pharm. Res. 15 (1998) 1657-1665
28. Fontaine M., Elmquist W.F., and Miller D.W. Use of Rhodamine-123 to examine the functional activity of P-Glycoprotein in primary cultured brain microvessel endothelial cell monolayers. Life Sci. 59 (1996) 1521-1531
29. Kihlberg J., Ahman J., Walse B., Drakenberg T., Nilsson A., Sodenberg-Ahlm C., Bengtsson B., and Olsson H. Glycosylated peptide hormones: pharmacological properties and conformational studies of analogs of [1-Desamino,8-d-arginine]vasopressin. J. Med. Chem. 38 (1995) 161-169
30. Elofsson M., Walse B., and Kihlberg J. Building blocks for glycopeptide synthesis: glycosylation of 3-mercaptopropionic acid and Fmoc amino acids with unprotected carboxyl groups. Tetrahedron Lett. 32 (1991) 7613-7616
31. Fessi H., Puisieux F., Devissaguet J.P., Ammoury N., and Benita S. Nanocapsule formation by interfacial polymer deposition following solvent displacement. Int. J. Pharm. 55 (1989) R1-R4
32. Chen H., Gaul F., Gou D., and Maycock A. Determination of loperamide in rat plasma and bovine serum albumin by LC. J. Pharm. Biomed. Anal. 22 (2000) 555-561
33. Iqbal T., Kinjo M., and Dowling T.C. Determination of Rhodamine 123 in cell lysate by HPLC with visible wavelength detection. J. Chromatogr. B. 814 (2005) 259-262
34. Xu Z., Pilch D.S., Srinivasan A.R., Olson W.K., Geacintov N.E., and Breslauer K.J. Modulation of nucleic acid structure by ligand binding induction of a DNA•RNA•DNA hybrid triplex by DAPI intercalation. Bioorg. Med. Chem. 5 (1997) 1137-1147
35. Eddy N.B., and Leimbach D. Synthetic analgesic. II. Dithienylbutyl and dithienylbutylamines. J. Pharm. Exp. Ther. 107 (1953) 385-395
36. Rezayat M., Rahnavard A., and Zarrindast M. Role of cholecystokinin receptors in induction of antinociception in hot-plate test. Pharmacol. Toxicol. 87 (2000) 58-62
37. Rafati H., Coombes A.G.A., Adler A., Holland J., and Davis S.S. Protein-loaded poly(d,l-lactide-co-glycolide) microparticles for oral administration: formulation structural and release characteristics. J. Control. Release 43 (1997) 89-102
38. Huang X., Chestang B.L., and Brazel C.S. Minimization of initial burst in poly(vinyl alcohol) hydrogels by surface extraction and surface-preferential crosslinking. Int. J. Pharm. 248 (2002) 183-192
39. Cohen S., Yoshioka T., Lucarelli M., Huang L.H., and Langer R. Controlled delivery systems for proteins based on poly(lactic/glycolic acid) microspheres. Pharm. Res. 8 (1991) 713-720
40. Sah H.K., Toddywala R., and Chien Y.W. The influence of biodegradable microcapsule formulations on the controlled release of a protein. J. Control. Release 30 (1994) 201-211
41. Batycky R.P., Hanes J., Langer R., and Edwards D.A. A theoretical model of erosion and macromolecular release from biodegrading microspheres. J. Pharm. Sci. 86 (1997) 1464-1477
42. Uchida K., Yagi A., Oda Y., and Goto S. Microencapsulation of ovalbumin in poly(lactide-co-glycolide) by and oil-in-oil (o/o) solvent evaporation method. J. Microencapsul. 13 (1996) 509-518
43. Zhang H., Cui W., Bei J., and Wang S. Preparation of poly(lactide-co-glycolide-co-caprolactone) nanoparticles and their degradation behaviour in aqueous solution. Polym. Degrad. Stab. 91 (2006) 1929-1936
44. Yoo H.S., Oh J.E., Lee K.H., and Park T.G. Biodegradable nanoparticles containing doxorubicin-PLGA conjugate for sustained release. Pharm. Res. 16 (2004) 1114-1118
45. Moghimi S.M., Hunter A.C., and Murray J.C. Long-circulating and target specific nanoparticles: theory to practice. Pharm. Rev. 53 (2001) 283-318
46. Tosi G., Rivasi F., Gandolfi F., Costantino L., Vandelli M.A., and Forni F. Conjugated poly(d,l-lactide-co-glycolide) for the preparation of in vivo detectable nanoparticles. Biomaterials 26 (2005) 4189-4195
47. Kreuter J., Alyautdin R.N., Kharkevich D.A., and Ivanov A.A. Passage of peptides through the blood-brain barrier with colloidal polymer particles (nanoparticles). Brain Res. 674 (1995) 171-174
48. Polt R., Dhanasekaran M., and Keyari C.M. Glycosylated neuropeptides: a new vista for neuropsychopharmacology?. Med. Res. Rev. 25 (2005) 557-585